San Francisco, CA (May 4, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission to FDA of the Chemistry, Manufacturing, and Controls (CMC) technical section of the New Animal Drug Application for KIND-010.
Richard Chin, M.D., President and CEO of KindredBio, stated, “We have been very pleased with the progress of the KIND-010 program for the management of weight loss in cats. Submitting the CMC technical section to FDA is a major milestone.”
The Company will host its first quarter 2016 financial results conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on May 5, 2016.
Interested parties may access the call by dialing toll-free (855) 433-0927 from the US, or (484) 756-4262 internationally, and using conference ID 98352561.
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. www.kindredbio.com